TorreyPines inititates dosing in Ph I pain trial
USA-based TorreyPines Therapeutics has initiated dosing of the first cohort of subjects in a Phase I trial of NGX426, the oral prodrug of its most advanced product candidate, tezampanel.
The double-blind, placebo-controlled, multiple dose trial will enroll a total of 20 healthy male and female adult volunteers in two sequential dose-escalating cohorts who will receive once-daily oral doses of placebo, 90mg or 150mg of NGX426 for five consecutive days. These same dose strengths of NGX426 are currently being evaluated by TorreyPines in a Phase I single dose capsaicin-induced hyperalgesia study to evaluate the analgesic effect of NGX426.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze